ProfileGDS5678 / 1438200_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 79% 83% 79% 84% 77% 79% 80% 80% 78% 75% 77% 80% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7614381
GSM967853U87-EV human glioblastoma xenograft - Control 25.5527279
GSM967854U87-EV human glioblastoma xenograft - Control 36.0257483
GSM967855U87-EV human glioblastoma xenograft - Control 45.6849479
GSM967856U87-EV human glioblastoma xenograft - Control 56.2642284
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1495577
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3419479
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.680180
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7099980
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.420178
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9802875
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2241177
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6615980
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2846677